Rocket Pharmaceuticals Inc
RCKTBuild a strategy around RCKT
Rocket Pharmaceuticals Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with -247M operating loss and 150M R&D spend - pure clinical-stage burn with no commercial validation yet.[Total Revenue TTM]
- Cash of 76M vs FCF burn of -203M TTM implies ~4.5 months runway without additional financing or asset sales.[Cash and Equivalents]
- Debt/equity of 0.08 with 314M equity provides dilution capacity, but 94M net investment sales TTM signals asset monetization underway.[Debt to Equity]
Watch Triggers
- Cash and Equivalents: Falls below 50M or rises above 150M — Below 50M = imminent dilution; above 150M = successful financing extends runway
- Total Revenue TTM: Any revenue recognition above zero — First revenue signals commercial launch and validates pipeline investment
- Research and Development TTM: Drops below 100M or rises above 200M — Sharp drop = pipeline cuts; increase = accelerated trials near approval
Bull Case
Clean balance sheet (0.08 D/E, 314M equity) provides financing flexibility. 150M R&D spend indicates advanced pipeline that could unlock value on approval.
Tangible book of 249M vs 25M total debt means asset base supports additional leverage or partnership deals without immediate equity dilution.
Bear Case
4-5 month cash runway at current burn forces near-term financing. Any capital raise at current stage likely highly dilutive to existing shareholders.
Zero revenue with -77% ROE TTM and -63% ROA means equity destruction continues until commercial launch - timeline unknown.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage RCKT's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: either secures financing/approval within 12 months or faces severe dilution/restructuring.
- 76M cash vs 203M annual burn rate
- Zero revenue requires capital markets access
- R&D of 150M suggests late-stage trials ongoing
Valuation Context
Caveats
RCKT Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$350.51M | — | ||
$325.67M | — | ||
0.00 | — | ||
$0 | — | ||
$-1.87 | — | ||
0% | — | ||
0% | — | ||
$-179.79M | — | ||
-64.4% | -4.0% | — | |
Beta 5Y (Monthly) | unknown | — |
RCKT Dividend History
RCKT Stock Splits
RCKT SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/07/26 | 03/31/26 | 10-Q | |
02/26/26 | 12/31/25 | 10-K | |
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
02/27/25 | 12/31/24 | 10-K | |
11/07/24 | 09/30/24 | 10-Q | |
08/06/24 | 06/30/24 | 10-Q | |
05/07/24 | 03/31/24 | 10-Q | |
02/27/24 | 12/31/23 | 10-K | |
11/07/23 | 09/30/23 | 10-Q | |
08/09/23 | 06/30/23 | 10-Q | |
05/05/23 | 03/31/23 | 10-Q | |
02/28/23 | 12/31/22 | 10-K | |
11/04/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/06/22 | 03/31/22 | 10-Q | |
02/28/22 | 12/31/21 | 10-K | |
11/05/21 | 09/30/21 | 10-Q | |
08/09/21 | 06/30/21 | 10-Q | |
05/10/21 | 03/31/21 | 10-Q | |
03/01/21 | 12/31/20 | 10-K | |
11/06/20 | 09/30/20 | 10-Q | |
08/05/20 | 06/30/20 | 10-Q | |
05/08/20 | 03/31/20 | 10-Q | |
03/06/20 | 12/31/19 | 10-K | |
11/08/19 | 09/30/19 | 10-Q | |
08/08/19 | 06/30/19 | 10-Q | |
05/09/19 | 03/31/19 | 10-Q | |
03/08/19 | 12/31/18 | 10-K | |
11/09/18 | 09/30/18 | 10-Q | |
08/14/18 | 06/30/18 | 10-Q | |
05/11/18 | 03/31/18 | 10-Q | |
03/07/18 | 12/31/17 | 10-K | |
11/08/17 | 09/30/17 | 10-Q | |
08/03/17 | 06/30/17 | 10-Q | |
05/10/17 | 03/31/17 | 10-Q | |
03/16/17 | 12/31/16 | 10-K | |
11/09/16 | 09/30/16 | 10-Q | |
08/10/16 | 06/30/16 | 10-Q | |
05/11/16 | 03/31/16 | 10-Q | |
03/23/16 | 12/31/15 | 10-K | |
11/12/15 | 09/30/15 | 10-Q | |
08/07/15 | 06/30/15 | 10-Q | |
05/14/15 | 03/31/15 | 10-Q | |
03/31/15 | 12/31/14 | 10-K | |
02/19/15 | 09/30/14 | 424B4 | |
08/07/15 | 06/30/14 | 10-Q | |
05/14/15 | 03/31/14 | 10-Q | |
02/19/15 | 12/31/13 | 424B4 |